MENU
+Compare
SPRY
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$17.87
Change
-$0.05 (-0.28%)
Capitalization
1.76B

SPRY ARS Pharmaceuticals Forecast, Technical & Fundamental Analysis

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis... Show more

SPRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SPRY with price predictions
Jul 25, 2025

SPRY saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for SPRY moved out of overbought territory on July 22, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 53 similar instances where the indicator exited the overbought zone. In of the 53 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SPRY moved out of overbought territory on June 30, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on July 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SPRY broke above its upper Bollinger Band on June 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 25, 2025. You may want to consider a long position or call options on SPRY as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 192 cases where SPRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SPRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.663) is normal, around the industry mean (18.028). P/E Ratio (152.500) is within average values for comparable stocks, (59.593). SPRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (18.904) is also within normal values, averaging (278.844).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SPRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

SPRY is expected to report earnings to rise 31.06% to -45 cents per share on August 06

ARS Pharmaceuticals SPRY Stock Earnings Reports
Q2'25
Est.
$-0.46
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.61
Q3'24
Missed
by $0.06
Q2'24
Missed
by $0.01
The last earnings report on May 14 showed earnings per share of -34 cents, missing the estimate of -34 cents. With 2.73M shares outstanding, the current market capitalization sits at 1.76B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11682 El Camino Real
Phone
+1 858 771-9307
Employees
26
Web
https://www.ars-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JLGIX22.160.10
+0.45%
JAG Large Cap Growth I
KSDIX16.880.05
+0.30%
Keeley Gabelli Small Cap Dividend I
FBKFX16.940.05
+0.30%
Fidelity Balanced K6
MIOLX29.350.02
+0.07%
Morgan Stanley Inst International Opp L
BTMPX18.39-0.02
-0.11%
iShares MSCI EAFE Intl Idx Inv P

SPRY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with XOMA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then XOMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
-0.28%
XOMA - SPRY
37%
Loosely correlated
N/A
RCUS - SPRY
35%
Loosely correlated
+3.65%
ANAB - SPRY
35%
Loosely correlated
-0.19%
OCUL - SPRY
35%
Loosely correlated
+2.43%
KROS - SPRY
33%
Loosely correlated
+0.56%
More